Background: Randomized trials have confirmed the benefits of adjuvant chemotherapy in improving survival in resected early-stage non-small-cell lung cancer (NSCLC). The extent to which these results have translated into clinical practice is unknown.
Objective: To examine the referral pattern of patients with resected lung cancer to adjuvant chemotherapy, and to compare compliance and toxicities with current literature.
Methods: A retrospective analysis of all patients who underwent a surgical resection for lung cancer at Laval Hospital (Quebec City, Quebec) from March 2004 to January 2006 was conducted.
Results: A total of 258 patients underwent surgery. Seven patients were excluded because of early postoperative death, and two patients were excluded because of incomplete data. Data from 249 patients were analyzed (94% NSCLC). Fifty per cent were referred to medical oncology for consideration of adjuvant chemotherapy, including 37 of 61 patients with stage II NSCLC. One hundred patients received chemotherapy. No significant difference in age, sex, comorbidities and surgical procedures was observed between those who received chemotherapy and those who did not. Chemotherapy was initiated 47 days (median) after the surgery and consisted mainly of cisplatin-vinorelbine (38%), cisplatin-etoposide (22%) and carboplatin-paclitaxel (20%). Sixty-six per cent of the patients completed all four cycles. Grade 3 or 4 toxicities consisted mainly of fatigue (23%) and cytopenia (40%). No death was registered; 15% had to be hospitalized because of adverse effects.
Conclusion: Although adjuvant chemotherapy is gaining acceptance in clinical practice, more patients should be referred to medical oncology following surgical resection. Compliance and toxicity are similar to or better than those described in published randomized trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679550 | PMC |
| http://dx.doi.org/10.1155/2008/462147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Renal Lymphoma: A Single-Center Study of 14 Cases.
Clin Genitourin Cancer
January 2025
Department of Pathology, The First Medical Centre, Chinese PLA General Hospital, Beijing, China. Electronic address:
Objective: To investigate the clinical characteristics, pathology, imaging features, and prognosis of primary renal lymphoma (PRL), a rare malignancy.
Patients And Method: We conducted a retrospective review of 14 PRL cases diagnosed between January 2009 and January 2022, with follow-up data collected from medical records.
Results: The study included 14 patients (7 males, 7 females), with a mean age of 60.
Is postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma?
Oral Oncol
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University Taoyuan Taiwan Republic of China. Electronic address:
Background: The current NCCN guidelines advocate for the use of adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) in pT3N0 oral cavity squamous cell carcinoma (OCSCC). Here, we sought to evaluate whether postoperative RT/CRT may confer a survival advantage in pT3N0 patients who lack adverse pathological features.
Methods: A dataset of 852 pT3N0 OCSCC patients treated between 2018 and 2021 was analyzed.
Malignant adenomyoepithelioma after breast cancer with multiple local recurrences.
Rev Esp Patol
January 2025
Breast Surgery, Breast Unit, Hospital Universitario Austral, Buenos Aires, Argentina.
Malignant adenomyoepithelioma of the breast is a rare and challenging tumor in terms of diagnosis and treatment. It is exceptional to find this condition in a patient who has had breast cancer treated with breast-conserving surgery and radiotherapy. We present the case of a 46-year-old female patient with a history of invasive lobular carcinoma of the breast, who presented one year later with a malignant adenomyoepithelioma in the same breast, which recurred three times, despite undergoing various surgical treatments and even adjuvant chemotherapy regimen.
View Article and Find Full Text PDFThe hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer.
Discov Oncol
January 2025
Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Non-small cell lung cancer (NSCLC) remains a dire disease being the first cause of cancer death among both genders. Early-stage NSCLC often has better treatment outcomes despite it being a highly heterogeneous disease. So far, the neo-adjuvant chemotherapy strategies have led to a small benefit with an improvement of 5% in overall survival as an absolute benefit.
View Article and Find Full Text PDFNew PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy.
Mol Pharm
January 2025
Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents with limited effective preventive or therapeutic interventions. Although fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPARα) agonist, has demonstrated neuroprotective and analgesic properties, its clinical utility is hindered by low receptor affinity, poor subtype selectivity, and suboptimal bioavailability. A190, a highly selective and potent nonfibrate PPARα agonist, offers a promising alternative but is limited by poor aqueous solubility, resulting in reduced oral bioavailability and therapeutic efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!